Angelis' salt (HNO/NO-) increased load-independent contractility by 47% and enhanced relaxation in failing canine hearts, independent of and additive to beta-adrenergic stimulation.
Congestive heart failure (n=20)
Angelis' salt (HNO/NO- donor) vs Baseline and NO donors (DEA/NO, NTG) (10 µg/kg per min, i.v.)
End-systolic elastance (Ees) in mmHg/ml, p=<0.001
Absolute Event Rate: 13.8% vs 9.51%
p-value: p=<0.001
Nitroxyl anion (HNONO(-)), the one-electron reduced form of nitric oxide (NO), induces positive cardiac inotropy and selective venodilation in the normal in vivo circulation. Here we tested whether HNO/NO(-) augments systolic and diastolic function of failing hearts, and whether contrary to NO/nitrates such modulation enhances rather than blunts beta-adrenergic stimulation and is accompanied by increased plasma calcitonin gene-related peptide (CGRP). HNO/NO(-) generated by Angelis' salt (AS) was infused (10 microg/kg per min, i.v.) to conscious dogs with cardiac failure induced by chronic tachycardia pacing. AS nearly doubled contractility, enhanced relaxation, and lowered cardiac preload and afterload (all P < 0.001) without altering plasma cGMP. This contrasted to modest systolic depression induced by an NO donor diethylamine(DEA)NO or nitroglycerin (NTG). Cardiotropic changes from AS were similar in failing hearts as in controls despite depressed beta-adrenergic and calcium signaling in the former. Inotropic effects of AS were additive to dobutamine, whereas DEA/NO blunted beta-stimulation and NTG was neutral. Administration of propranolol to nonfailing hearts fully blocked isoproterenol stimulation but had minimal effect on AS inotropy and enhanced lusitropy. Arterial plasma CGRP rose 3-fold with AS but was unaltered by DEA/NO or NTG, supporting a proposed role of this peptide to HNO/NO(-) cardiotropic action. Thus, HNO/NO(-) has positive inotropic and lusitropic action, which unlike NO/nitrates is independent and additive to beta-adrenergic stimulation and stimulates CGRP release. This suggests potential of HNO/NO(-) donors for the treatment of heart failure.
Building similarity graph...
Analyzing shared references across papers
Loading...
Nazareno Paolocci
Heart Failure & Transplant
Tatsuo Katori
Showa General Hospital
Hunter C. Champion
Heart Failure & Transplant
Proceedings of the National Academy of Sciences
Johns Hopkins University
University of California, Los Angeles
National Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Paolocci et al. (Fri,) conducted a other in Congestive heart failure (n=20). Angelis' salt (HNO/NO- donor) vs. Baseline and NO donors (DEA/NO, NTG) was evaluated on End-systolic elastance (Ees) in mmHg/ml (p=<0.001). Angelis' salt (HNO/NO-) increased load-independent contractility by 47% and enhanced relaxation in failing canine hearts, independent of and additive to beta-adrenergic stimulation.
synapsesocial.com/papers/6a14f5f69ff8b2b0e129e02b — DOI: https://doi.org/10.1073/pnas.0937302100
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: